• NEWS & PUBLICATIONS
  • News and Media
  • Newsletters
  • Journals
  • Books
• MEMBERSHIP
  • Join/Renew
  • Benefits
  • Categories
  • Download a Member Application
  • Grants, Awards, and Scholarships
  • Access the Phantom Analysis Toolkit
  • Membership Directory
  • Chapters
  • Centers of Excellence
  • Councils
  • Member Spotlight
  • Women in Nuclear Medicine
  • SNMMI Fellow
  • SNMMI-TS Fellow
  • Council and Center Internships
• EDUCATION
  • Learning Center
  • Webinars
• MEETINGS & EVENTS
  • Calendar of Events
  • Webinars
  • 2024 Annual Meeting
  • 2024 Therapeutics Conference
  • 2024 Mid-Winter Meeting
  • Nuclear Medicine & Molecular Imaging Week
• ADVOCACY
  • Coding & Reimbursement
  • Legislative Efforts
  • Government Relations News
  • Radiopharmaceutical Supply News
  • USP 825
  • Technologist State Issues
  • Position Statements
  • FDA PET Drug Manufacturing Q&A
• EVIDENCE & QUALITY
  • Clinical Guidelines and AUC
  • Quality
  • Quality and Patient Safety
  • Dose Optimization
  • About Quality & Practice
  • Dosimetry
• RESEARCH
  • Clinical Trials Network
  • Radiopharmaceutical Therapy Central
  • Radiopharmaceutical Therapy Centers of Excellence
  • Preclinical Imaging
  • Nuclear Medicine Clinical Trial Group, LLC
  • Research: Learn More
• ABOUT SNMMI
  • Strategic Plan
  • Bylaws & Procedures
  • Governance - SNMMI
  • Governance - SNMMI-TS
  • History
  • Grants, Awards, and Scholarships
  • Career Center
  • About Nuclear Medicine & Molecular Imaging
  • International Collaboration
  • Outreach
  • Support SNMMI
  • Contact Us

SNMMI News

• New SPECT/CT Technique Shows Impressive Biomarker Identification, Offers Increased Access for Prostate Cancer Patients

  Apr 16, 2024 — A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment, according to new research in JNM.

• PET/MRI Accurately Classifies Prostate Cancer Patients, Offers Potential to Avoid Unnecessary Biopsies

  Apr 11, 2024 — PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in JNM.

• HFR Reactor Restart Delayed; Some Disruption to Mo-99 Supply Expected

  Apr 9, 2024 — The NRG communicated that a deviation had been found in the cooling system of the Petten High Flux Reactor, which delayed the restart of HFR for its next cycle.

• Novel Theranostic Tool Allows for Noninvasive Identification and Treatment of Ovarian Cancer

  Apr 3, 2024 — A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of JNM.

• UPTAKE: A Dialogue with Future Leaders

  Mar 25, 2024 — This fall, SNMMI-TS member Jacquelyn Brogley visited nuclear medicine students at her alma mater, Gateway Community College in Phoenix, AZ. Hear her advice to them and how the day left her inspired for the future of the field.

• New Method for Triggering and Imaging Seizures Can Help Guide Epilepsy Surgery

  Mar 11, 2024 — Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery, according to new research published in The Journal of Nuclear Medicine.

• Novel PET Tracer Maps Fructose Metabolism to Identify Cardiac and Neural Disorders

  Mar 7, 2024 — A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in The Journal of Nuclear Medicine.

• Cannabis and Weight Loss Drugs Impact Nuclear Medicine Gastrointestinal Scans

  Mar 5, 2024 — The use of marijuana and new weight loss pharmaceuticals can impact gastric emptying scans commonly used to evaluate patients with gastrointestinal complaints, according to research published in the Journal of Nuclear Medicine Technology.

• Message from the President

  Mar 5, 2024 — SNMMI President Helen Nadel highlights recent achievements, global collaborations, advocacy efforts, and upcoming SNMMI meetings.

• Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Newly Diagnosed Prostate Cancer Patients

  Mar 5, 2024 — Radioguided surgery can detect and remove metastatic pelvic lymph nodes in patients newly diagnosed with prostate cancer, according to research published in the March issue of The Journal of Nuclear Medicine.

• Uptake: 5 Tips for 5-Star PET Scans

  Feb 22, 2024 — Take 5-star images with every PET scan! Today, we’re highlighting 5 tips to ensure that your PET scans are clear, accurate, and reproducible. Consistent imaging is effective imaging!

• In Memoriam: Gerald DeNardo, MD

  Feb 21, 2024 — Gerald DeNardo, MD, professor emeritus of internal medicine and radiology at the University of California–Davis, passed away on February 11, 2024.

• JNM Outlines the Future of Theranostics in Neurooncology

  Feb 15, 2024 — Nuclear medicine has the potential to change the landscape of theranostics in neurooncology, according to a new article in JNM. With recent advances in techniques to permeate the brain-blood barrier, the prospect of using radiopharmaceuticals to treat brain tumors is promising.

• Radiopharmaceutical Therapy Controls Symptoms and Reduces Medications in Insulinoma Patients

  Feb 12, 2024 — PRRT is effective for clinical control of symptomatic metastatic insulinomas, according to new research published in JNM. In the largest study to date of metastatic insulinoma patients treated with PRRT, more than 80 percent of patients had long-lasting symptom control, and nearly 60 percent were able to reduce the use of other drugs to treat the disease.

• New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear

  Feb 8, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body —such as rheumatoid arthritis—before clinical symptoms arise, according to research published in JNM.

• SNMMI Mid-Winter and ACNM Annual Meeting Highlights Advances in Nuclear Medicine and Molecular Imaging

  Feb 5, 2024 — More than 700 attendees from around the world gathered in Orlando, Florida, on February 1-3 for the SNMMI Mid-Winter and ACNM Annual Meeting.

• UPTAKE: Empowering Technologists: Introducing the Technologist Advocacy Group (TAG)

  Jan 22, 2024 — The Technologist Advocacy Group (TAG) is an integral part of the SNMMI Technologist Section. How can TAG help you and the profession?

• New PET/CT Technique Accurately Diagnoses Adrenal Gland Disorder, Informs Personalized Treatment Plans

  Jan 18, 2024 — A novel imaging approach, Ga-68 pentixafor PET/CT, has been shown to accurately identify sub-types of primary aldosteronism, outperforming traditional methods for diagnosis, according to research published in JNM.

• Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer, Offers Potential for Targeted Therapy

  Jan 11, 2024 — A newly developed PET imaging agent has been found to be effective in identifying medullary thyroid cancer in preclinical and clinical studies, according to research published in JNM.

• 2024 SNMMI CIC Imaging Case Competition

  Jan 5, 2024 — The SNMMI Correlative Imaging Council will host its 1st annual Correlative Imaging Case Competition at this year’s SNMMI Annual Meeting, June 8-11 in Toronto, Canada. Enter now!

• JNM Publishes Procedure Standard/Practice Guideline for FES PET Imaging of Breast Cancer

  Jan 5, 2024 — SNMMI and EANM have issued a new procedure standard/practice guideline for estrogen receptor imaging of breast cancer patients using FES PET.

• FDA Approves New Pluvicto Production Facility in Indianapolis

  Jan 5, 2024 — Today Novartis announced that it has received FDA approval for its radioligand therapy manufacturing facility in Indianapolis for commercial manufacturing of Pluvicto.

• Ga-68 FAPI PET Improves Detection and Staging of Pancreatic Cancer

  Dec 20, 2023 — PET imaging with Ga-68 FAPI can more effectively detect and stage pancreatic cancer as compared with 18F-FDG imaging or contrast-enhanced CT, according to new research published in JNM. In addition, Ga-68 FAPI imaging paves the way for future targeted radiopharmaceutical therapies.

• New PET Tracer Noninvasively Identifies Cancer Gene Mutation, Allows for More Precise Diagnosis and Therapy

  Dec 19, 2023 — A novel PET imaging tracer has been proven to safely and effectively detect a common cancer gene mutation that is an important molecular marker for tumor-targeted therapy, according to research published in The Journal of Nuclear Medicine.

• Uptake: Words of Wisdom from Recent Graduates

  Dec 15, 2023 — Hang in there, students! Words of wisdom from recent graduates

• SNMMI Releases New Edition of PET Study Guide

  Nov 29, 2023 — SNMMI is pleased to announce the release of the third edition of its popular PET Study Guide. The updated version incorporates the latest innovations in imaging technology and FDA-approved PET radiopharmaceutical and imaging techniques and practices.

• Journal of Nuclear Medicine Supplement Explores Nuclear Cardiology

  Nov 20, 2023 — A new JNM supplement highlights the exciting new developments and opportunities for nuclear cardiology in the modern era of personalized cardiovascular medicine.

• SNMMI Holds Joint Workshop with FDA on PET Drug Regulations

  Nov 16, 2023 — On November 13 and 14, SNMMI co-hosted a workshop on PET drug manufacturing with the FDA.

• Novel PET Radiotracer Facilitates Early, Noninvasive Detection of Inflammatory Bowel Disease

  Nov 14, 2023 — A newly developed PET radiotracer can be used to create an inflammation map of the entire gastrointestinal tract, providing detailed information to accurately detect and stage inflammatory bowel disease, according to research published in JNM.

• Uptake: Unrest In the Healthcare Workforce

  Nov 10, 2023 — Rising supply costs, reimbursement pressures, labor shortages, and and more are affecting nuclear medicine technologists. SNMMI-TS is working on initiatives that will help.

• Bone Scans Overstage Prostate Cancer at Initial Staging Compared with PSMA PET

  Nov 9, 2023 — Bone scans have been found to overstage prostate cancer at initial staging compared to PSMA PET, according to new research published in JNM.

• SNMMI Statement on Israel and Gaza

  Oct 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging strongly condemns the recent terrorism in Israel and war in Gaza.

• New AI Tool for PET Imaging Allows for High-Quality, Fully Automated Evaluation of Brain Tumors

  Oct 17, 2023 — A new artificial intelligence tool provides a fully automated, easy-to-use and objective way to detect and evaluate brain tumors, according to new research published in JNM.

• CMS Removes NCD for Beta Amyloid PET

  Oct 13, 2023 — CMS announced today the removal of the NCD for beta-amyloid PET scans, expanding access for patients with Alzheimer's disease and other neurodegenerative diseases.

• PET Imaging Validates Use of Common Cholesterol Drug to Enhance HER2-Targeted Cancer Therapy

  Oct 12, 2023 — A novel therapeutic approach combining HER2-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor growth, according to research published in JNM.

• Message from the President

  Oct 10, 2023 — SNMMI President Helen Nadel highlights recent achievements, global collaborations, advocacy efforts, and upcoming SNMMI meetings.

• NorthStar Medical Radioisotopes To Suspend Production of Mo-99

  Oct 6, 2023 — NorthStar Medical Radioisotopes will suspend manufacturing and commercialization of Mo-99 at the end of 2023.

• Novel Tau PET Tracer Exhibits High Sensitivity and Specificity, Allowing for Earlier Identification of Alzheimer’s Disease

  Sep 29, 2023 — A new tau PET radiotracer, F-18 SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimer’s disease in its earliest stages, according to research published in JNM.

• FDA Approves Widely Used Imaging Agent for Respiratory Disease

  Sep 29, 2023 — The FDA has approved the imaging agent Technegas for use in ventilation–perfusion studies to diagnose pulmonary embolism and other respiratory pathologies.

• Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients

  Sep 28, 2023 — A new imaging agent, Ga-68-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in JNM.

• Just published: A Practical Guide for Pediatric Nuclear Medicine

  Sep 26, 2023 — A new open access book has just been published covering important aspects of nuclear medicine in children and the differences between adult and pediatric practice.

• First Three Facilities Accredited in SNMMI/IAC Radiopharmaceutical Therapy Accreditation Program

  Sep 25, 2023 — SNMMI and the Intersocietal Accreditation Commission are pleased to announce the first three facilities to be awarded the new Radiopharmaceutical Therapy Accreditation.

• SNMMI Issues Updated Statement: COVID-19 and V/Q Lung Studies

  Sep 18, 2023 — SNMMI has issued an updated statement about COVID-19 and ventilation/perfusion (V/Q) lung studies

• Nuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting

  Sep 18, 2023 — A new 225Ac-DOTA-based pre-targeted radioimmunotherapy system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects, according to research published in JNM.

• Uptake: Growth of Fusion Imaging

  Sep 15, 2023 — Since the introduction of SPECT/CT two decades ago, nuclear medicine has become intertwined with CT, thus requiring that technologist education provide a strong background in CT as well. Avenues for dual certification should be made more accessible to benefit technologists and hospital systems alike.

• JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy

  Sep 1, 2023 — SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with Lu-177 PSMA radionuclide therapy.

• New: Consensus Recommendation for PET/MRI in Oncology

  Aug 28, 2023 — A consensus recommendation for PET/MRI in oncologic imaging in adults has been released by the SNMMI, the EANM, and the ISMRM.

• SNMMI Supports CMS’s Proposed Changes to Beta-Amyloid PET Coverage

  Aug 22, 2023 — SNMMI submitted comments to CMS in response to its proposed removal of the current NCD for beta-amyloid PET.

• Lantheus to Discontinue Production of Azedra

  Aug 18, 2023 — Lantheus will discontinue production of Azedra (iobenguane I-131), its FDA-approved therapy for pheochromocytoma/paraganglioma (PPGL).

• PSMA PET/CT Waives the Need for Pre-Imaging Biopsy in Elderly Patients

  Aug 14, 2023 — In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy, according to new research published in JNM.

• SNMMI Announces Ones to Watch 2023 Selections

  Aug 7, 2023 — SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2023!

• 2024 Ones to Watch Nominations

  Aug 7, 2023 — SNMMI is now accepting nominations for our 2024 Ones to Watch selections. We need your help in identifying and recognizing “ones to watch” in the coming years, as they work to shape the future of nuclear medicine and molecular imaging. Members can nominate someone they know—currently in training or who have completed their training within the last 10 years—whose actions, work, or studies have set them apart as a future thought leader in the field.

• Message from the President

  Aug 3, 2023 — Since the Annual Meeting, SNMMI has been hard at work increasing access to nuclear medicine, planning for upcoming meetings, strengthening its relationships with colleagues around the world, and working with members to develop programs that meet their wants and needs.

• CMS Proposes Removal of National Coverage Determination for Beta Amyloid PET

  Jul 18, 2023 — SNMMI applauds the recent CMS proposal to remove the national coverage determination for beta amyloid PET, ending the coverage with evidence development requirements and allowing MACS to determine appropriate coverage for these scans.

• DOE Isotope Program Issues Annual Update

  Jul 14, 2023 — The DOE Isotope Program has issued an FY2023 annual update for federal agencies and stakeholders.

• FDA Fully Approves Leqembi for Alzheimer’s; CMS Unclear on PET Reimbursement

  Jul 10, 2023 — The FDA has granted full approval to Leqembi (lecanemab); however, CMS has not committed to reimbursement of the needed PET scans.

• Dipyridamole Shortage in Canada

  Jul 7, 2023 — Due to production delays, dypyridamole is currently in short supply in Canada. This shortage poses a significant challenge to healthcare providers across the country, potentially impacting patient care and treatment outcomes.

• SNMMI Keeps “Eye on the Patient” at 2023 Annual Meeting

  Jun 28, 2023 — SNMMI hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed “Eye on the Patient,” held in Chicago, Illinois.

• Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

  Jun 27, 2023 — A novel PET perfusion radiotracer, F-18 flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to Tc-99m SPECT myocardial perfusion imaging, according to research presented at the 2023 SNMMI Annual Meeting.

• Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

  Jun 27, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy.

• Personalized Dosing in Prostate Cancer Treatment Improves Patient Outcomes

  Jun 27, 2023 — By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.

• Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease

  Jun 27, 2023 — A new computational technique that combines genomic and tau PET imaging data promises a more personalized approach for subtyping Alzheimer’s disease.

• Novel Theranostic Agent Targets Multiple Cancer Types

  Jun 27, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach.

• Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

  Jun 26, 2023 — Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for Precision Imaging, and associate chair for imaging sciences in the Department of Radiology at Massachusetts General Hospital and professor of radiology at Harvard Medical School in Boston, has been named as the first recipient of the new Minoshima-Pappas Transformational Leadership Award.

• Peter J. H. Scott, PhD, Receives SNMMI Sam Gambhir Trailblazer Award

  Jun 26, 2023 — Peter J. H. Scott, PhD, associate professor of radiology and pharmacology, division director of nuclear medicine, and director of the PET Center at the University of Michigan in Ann Arbor, Michigan, has been named as the 2023 recipient of the Sam Gambhir Trailblazer Award.

• SNMMI Elects Jean-Luc C. Urbain, MD, PhD, FASNC, as Vice President-Elect at 2023 Annual Meeting

  Jun 26, 2023 — Jean-Luc C. Urbain, MD, PhD, FASNC, professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo in New York, has been elected vice president-elect for the SNMMI.

• SNMMI Names Helen Nadel, MD, FRCPC, as President at 2023 Annual Meeting

  Jun 26, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, in Stanford, California, has been named president of the SNMMI.

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as President-Elect at 2023 Annual Meeting

  Jun 26, 2023 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as president-elect for the SNMMI.

• Novel Radiotracer Accurately Detects and Differentiates Renal Cell Carcinomas

  Jun 26, 2023 — A new PET tracer, Zr-89 DFO-girentuximab, can accurately detect a type of kidney cancer called clear cell renal cell carcinoma and differentiate it from other types of kidney tumors.

• New Radiopharmaceutical Therapy Target Identified for Metastatic Bladder Cancer

  Jun 26, 2023 — A new therapeutic target has been discovered for metastatic bladder cancer, opening up the door for more effective detection and treatment of this deadly disease.

• Society of Nuclear Medicine and Molecular Imaging Announces 2023 Fellows

  Jun 26, 2023 — SNMMI recognized ten new SNMMI Fellows today during a plenary session at the society’s 2023 Annual Meeting.

• SNMMI Image of the Year: New Theranostic Pair Facilitates Early Detection and Effective Treatment of Pancreatic Cancer

  Jun 26, 2023 — A first-in-human evaluation of the novel theranostic pair Ga-68 DOTA-5G / Lu-177 DOTA-ABM-5G has confirmed its ability to successfully detect metastatic pancreatic cancer and visualize targeted treatment of the disease. A grouping of the resulting images has been selected as the 2023 SNMMI Henry N. Wagner, Jr., Image of the Year.

• Henry VanBrocklin, PhD, FSNMMI, FSRS, Receives SNMMI 2023 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 25, 2023 — Henry VanBrocklin, PhD, has been named the 2023 recipient of the prestigious Paul C. Aebersold Award.

• Translational PET Tracer Visualizes Brain Cholesterol Metabolism

  Jun 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated, according to research presented at the 2023 SNMMI Annual Meeting.

• SNMMI and IAC Collaborate on New Radiopharmaceutical Therapy Accreditation Program

  Jun 25, 2023 — SNMMI and the Intersocietal Accreditation Commission are pleased to announce an enhanced partnership that will help ensure quality care for patients receiving radiopharmaceutical therapy.

• Nizar A. Mullani, BS, Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 25, 2023 — Nizar A. Mullani, BS, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• SNMMI Announces Julie Dawn Bolin, MS, CNMT, as President-Elect of the Technologist Section During 2023 Annual Meeting

  Jun 25, 2023 — Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College in Phoenix, Arizona, and nuclear medicine technologist at Banner Staffing Services in Tucson, Arizona, has been elected 2023-24 president-elect for the SNMMI-TS.

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President of the Technologist Section During 2023 Annual Meeting

  Jun 25, 2023 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2023-24 president for the SNMMI-TS.

• SNMMI Abstract of the Year: Novel Molecularly Targeted I-131 Apamistamab Enables Marrow Transplantation with Long-term Survival in Relapsed/Refractory Acute Myeloid Leukemia

  Jun 25, 2023 — Personalized dosing of Iomab-B (I-131 apamistamab), has been shown to successfully enable relapsed and/or refractory acute myeloid leukemia (AML) patients with active disease to successfully receive potentially life-saving bone marrow transplantation.

• New PET Model for Quantifying Cardiac Amyloidosis Allows for More Accurate Diagnosis and Monitoring

  Jun 25, 2023 — Researchers have identified the optimal tracer kinetic model to quantify 18F-flutemetamol myocardial uptake in patients with transthyretin (ATTR) cardiac amyloidosis.

• FAPI PET Imaging Accurately Assesses Disease Activity in Rheumatoid Arthritis

  Jun 25, 2023 — PET imaging with Ga-68 FAPI offers a feasible, reliable, and reproducible method for evaluating disease activity in rheumatoid arthritis, according to new research presented at the 2023 SNMMI Annual Meeting.

• New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

  Jun 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.

• Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

  Jun 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously indistinguishable brain regions that are known to be involved in Alzheimer’s disease, depressive disorders, visual attention disorders, tinnitus, and other conditions.

• Nuclear Medicine Global Initiative Reports Worldwide Challenges and Opportunities in Theranostics Education

  Jun 23, 2023 — Leaders from 12 nuclear medicine organizations around the world have issued a white paper about the challenges and opportunities in theranostics education.

• Pretherapy Imaging and Dosimetry Offer Personalized Treatment Planning for Thyroid Cancer Patients

  Jun 22, 2023 — JNM: A combination of pretherapy imaging and dosimetry can help ensure that patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following redifferentiation therapy.

• Novel Imaging Agent Allows for Earlier Detection of Progressive Pulmonary Fibrosis

  Jun 20, 2023 — JNM: A newly developed PET imaging agent can non-invasively identify pulmonary fibrosis in its early stages, reducing the need for unnecessary biopsies and allowing patients to begin treatment sooner.

• Interested in the Nuclear Medicine Career Interest Program?

  Jun 20, 2023 — This interest program information session gives students the opportunity to learn about job details, educational requirements and opportunities available for a future career in nuclear medicine.

• Ellison, Scott and Sanford Receive SNMMI Mars Shot Fund Award

  Jun 12, 2023 — SNMMI is excited to announce Paul Ellison, PhD, Peter J. H. Scott, PhD, and Melanie S. Sanford, PhD, have been selected as the recipients of a $500,000 grant from the 2023 Mars Shot Fund.

• Amir Iravani, MD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Amir Iravani, MD, has been selected as the recipient of a $1,000,000 SNMMI Mars Shot Fund Grant.

• Craig Levin, PhD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Craig Levin, PhD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund.

• Randy Yeh, MD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Randy Yeh, MD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Research Fund.

• Julie Sutcliffe, PhD, Receives SNMMI Mars Shot Fund Award

  Jun 7, 2023 — SNMMI is excited to announce that Julie Sutcliffe, PhD, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund.

• Make Connections—Unlock the Power of Networking

  May 17, 2023 — Are you looking to take your career to the next level? Do you want to make valuable connections that can help you achieve your professional goals?

• Celebrate Clinical Trials Day with the SNMMI Clinical Trials Network!

  May 15, 2023 — The SNMMI Clinical Trials Network (CTN) is celebrating Clinical Trials Day on Saturday, May 20!

• Amino Acid PET Successfully Differentiates Recurrent Brain Metastases, Reducing Invasive Procedures and Overtreatment

  May 12, 2023 — A new meta-analysis indicates that amino acid PET can accurately differentiate recurrent or progressive brain metastases from treatment-related changes, potentially reducing overtreatment, according to research published in May JNM.

• New Research: FAPI PET Imaging Superior for Diagnosing Multiple Types of Cancer, with Potential for Targeted Treatment

  May 1, 2023 — Two articles in the May issue of JNM illustrate the promise of the novel FAPI radiotracer. Results from the largest study of patients undergoing 68Ga-FAPI PET demonstrate the superiority of 68Ga-FAPI over standard 18F-FDG PET in evaluating multiple types of cancer. In a separate study, a newly designed FAPI-targeted treatment was found to suppress tumor growth in several common cancers in a preclinical setting. These advances have strong potential to provide more precise staging and management for cancer patients.

• Novartis Announces FDA Approval for New Jersey Facility to Produce Pluvicto for Commercial Use

  Apr 21, 2023 — Today Novartis announced that it has received FDA approval to supply Pluvicto from its plant in Millburn, New Jersey. The company is planning to ramp up production in the coming weeks.

• SNMMI Celebrates National Volunteer Week

  Apr 20, 2023 — A special thank you to all our members who volunteer their time, talent, and expertise to meet the critical needs of the nuclear medicine and molecular imaging community.

• Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy

  Apr 19, 2023 — International, multicenter testing demonstrated the effectiveness of a newly established PSMA PET scoring system that can successfully predict whether metastatic castration-resistant prostate cancer patients will respond to treatment with Lu-177 PSMA therapy. The research was published online in JNM.

• JNM Publishes Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema

  Apr 14, 2023 — SNMMI and 10 other professional societies have issued appropriate use criteria for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The criteria are summarized in the April issue of JNM.

• New Nuclear Medicine Therapy Cures Human Non-Hodgkin Lymphoma in Preclinical Model

  Apr 11, 2023 — A single dose of the radioimmunotherapy can cure human non-Hodgkin lymphoma in an animal model, according to research published in the April issue of The Journal of Nuclear Medicine.

• Blood-Based Biomarkers Accurately Predict Neuroendocrine Tumor Response to Radiopharmaceutical Therapy

  Apr 6, 2023 — A simple blood draw can provide physicians with valuable information about whether PRRT is likely to be effective in a patient with neuroendocrine cancer—opening new possibilities for tailoring radiopharmaceutical treatment to patients. The research is published in the April issue of JNM.

• Molecular Imaging Offers Insight Into Chemo-Brain

  Mar 28, 2023 — A new literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain. This information—published ahead-of-print in JNM—can help patients better understand the changes in their cognitive status during and after treatment.

• JNM Explores Potential Applications for ChatGPT in Nuclear Medicine and Molecular Imaging

  Mar 27, 2023 — In a new JNM article, Irène Buvat, PhD, and Wolfgang Weber, MD, PhD, explore the potential for using AI chatbot ChatGPT in the field of nuclear medicine and molecular imaging.

• PSMA PET Improves Decision Making for Prostate Cancer Treatment

  Mar 24, 2023 — PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may unnecessarily irradiate healthy tissues, according to a new study published ahead of print in JNM. Researchers are calling for redefinition of the guidelines to improve patient outcomes.

• New Compact and Low-Cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging

  Mar 21, 2023 — A novel, palm-sized imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in March JNM. Known as the lensless radiomicroscope, the instrument offers the same level of imaging performance as its closest imaging equivalent but comes with significantly larger field of view and costs less than $100.

• Update, Pluvicto Supply Shortage: How You Can Help

  Mar 20, 2023 — Due to severe production issues, the supply of Pluvicto is not currently sufficient to meet patient need. Please act now!

• Novel PET Radiotracer Successfully Detects Multiple Cancers, Offers Potential for New Targeted Radionuclide Therapy

  Mar 16, 2023 — A new radiotracer, Ga-68 FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, F-18 FDG, according to a study published in JNM. Ga-68 FAP-2286 detected 100 percent of primary tumors across multiple cancer types as compared to F-18 FDG, which identified only 80 percent. Ga-68 FAP-2286 was also more effective in detecting lymph node metastases and distant metastases.

• Pluvicto Supply Shortage Update: What SNMMI Is Doing

  Mar 8, 2023 — A supply problem with Pluvicto, the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients, which is having a profound negative impact on patient care.

• SNMMI Applauds Introduction of FIND Act of 2023: Legislation Will Ensure Patient Access to Innovative and Effective Diagnostic Imaging

  Mar 6, 2023 — SNMMI, along with more than 80 stakeholder organizations, supports and applauds the introduction of H.R. 1199, the Facilitating Innovative Nuclear Diagnostic (FIND) Act of 2023. The legislation will ensure patient access to innovative and effective diagnostic imaging.

• SNMMI Mars Shot/Lobular Breast Cancer Alliance Announce Recipient of the Invasive Lobular Carcinoma Imaging Research Fellowship

  Mar 1, 2023 — The SNMMI Mars Shot Research Fund and the Lobular Breast Cancer Alliance (LBCA) are excited to announce that Marina Sharifi, MD, PhD, has been selected as the recipient of the joint SNMMI/LBCA Invasive Lobular Carcinoma Imaging Research Fellowship.

• JNM Publishes Procedure Standard/Practice Guideline for SSTR PET Imaging of Neuroendocrine Tumors

  Feb 21, 2023 — SNMMI and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline to assist physicians in recommending, performing, interpreting, and reporting the results of somatostatin receptor (SSTR) PET imaging for patients with neuroendocrine tumors. The guideline is published in the February issue of The Journal of Nuclear Medicine.

• New Dual-Phase Imaging Protocol Reduces Costs and Radiation Exposure for Cognitively Impaired Patients

  Feb 8, 2023 — A new nuclear medicine imaging protocol can assess both amyloid and neurodegeneration with a single tracer injection, cutting costs and radiation exposure for patients as well as providing them greater comfort. This research was published in the February issue of The Journal of Nuclear Medicine.

• E-Cigarettes Potentially Harmful: PET Imaging Shows Greater Lung Inflammation in E-Cigarette Users Than Cigarette Smokers

  Jan 25, 2023 — PET imaging shows greater lung inflammation in e-cigarette users than in cigarette smokers, according to a new study published ahead of print in JNM.

• Nearly Half of Medicare Patients with Non-Small Cell Lung Cancer Not Staged According to National Guidelines: Lack of Adherence Linked to Greater Mortality Rates

  Jan 17, 2023 — A study published in the January JNM reports that approximately half of Medicare patients with NSCLC do not receive the appropriate imaging prior to radiation therapy. Significant improvement in survival rates was found in patients who had FDG PET/CT imaging—as recommended in NCCN guidelines—compared to those who underwent CT imaging alone.

• Novel PET Radiotracer Reduces Number of False-Positive Cancer Findings After COVID-19 Vaccination

  Jan 10, 2023 — A novel imaging agent, Ga-68 FAPI, can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19, helping prevent costly follow-up and false management decisions for cancer patients.

• FDA Approves New Treatment for Alzheimer's Disease: Presence of Beta Amyloid Must Be Confirmed Before Treatment

  Jan 6, 2023 — A new treatment for Alzheimer’s disease, lecanemab, was approved today by the FDA. Lecanemab has been shown to slow the progression of Alzheimer’s for patients who are in early stages of the disease. Prescribing information instructs physicians to “confirm the presence of amyloid beta pathology prior to initiating treatment.”

• PSMA PET/MRI Accurately Predicts Risk of Prostate Cancer Recurrence

  Jan 5, 2023 — In men recently diagnosed with intermediate or high-grade prostate cancer, PSMA PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

• Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

  Jan 3, 2023 — Approximately 3% of bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality, according to new research published in JNM. This incidental finding may offer a window of opportunity for treatment.

• Congress passes 2023 Consolidated Appropriations Act

  Dec 29, 2022 — On December 23, 2022, the U.S. House of Representatives passed H.R. 2617, the 2023 Consolidated Appropriations Act (also referred to as the Omnibus package) by a vote of 225-201-1.

• This Month in JNM

  Dec 1, 2022 — In December JNM: A discussion with GU oncologist Declan Murphy … The State of the Art: FAPI PET/CT in nonmalignant diseases … Continuing Education: FDA approval for theranostic agents … Focus on MI: Nanoparticle diagnostics and theranostics … Featured: a-Particle and immunocytokine therapy … Cardiac amyloidosis in bone scan referrals … and more.

• Novel PET Agent Effectively Detects Multiple Cancers, Identifies Patients for Targeted Therapies

  Nov 17, 2022 — A new molecular imaging radiotracer, Ga-68 PentixaFor, can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

• 2023 Ones to Watch Nominations

  Nov 16, 2022 — SNMMI is now accepting nominations for our 2023 Ones to Watch selections. We need your help in identifying and recognizing “ones to watch” in the coming years, as they work to shape the future of nuclear medicine and molecular imaging. Members can nominate someone they know—currently in training or who have completed their training within the last 10 years—whose actions, work, or studies have set them apart as a future thought leader in the field.

• SNMMI Announces Ones to Watch 2022 Selections

  Nov 16, 2022 — SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2022!

• PET/MRI Machine Learning Model Can Eliminate Sentinel Lymph Node Biopsy in Majority of Breast Cancer Patients

  Nov 10, 2022 — Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy, according to new research published in JNM.

• Pomper Wins Minnie’s 2022 Most Influential Radiology Influencer for F-18 DCFPyL

  Oct 27, 2022 — Martin Pomper, MD, PhD, has been named Most Influential Radiology Researcher for 2022 by AuntMinnie for his work in developing F-18 DCFPyL.

• CTN: Enabling Accurate Quantitative PET/CT and SPECT/CT Imaging

  Oct 25, 2022 — Quantitative measurements have long been a strength of nuclear medicine. There is renewed urgency for accurate, reproducible, and standardized measurements in routine clinical practice as the role of diagnostic and therapeutic radiopharmaceuticals in clinical trials and routine clinical care grows. The CTN continues to be involved in this space, with several active projects to address this need.

• Novel PET Imaging Agent Detects Earliest Signs of Alzheimer’s Disease

  Oct 19, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B (MAO-B) in cognitively unimpaired individuals with high beta amyloid, according to research published in the October issue of JNM.

• Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis

  Oct 12, 2022 — Total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis, according to new first-in-human research published in the October issue of JNM.

• SNMMI and the Lobular Breast Cancer Alliance Announce $100,000 Research Grant

  Oct 3, 2022 — SNMMI announces a new $100,000 grant to fund research on nuclear medicine imaging and treatments for lobular beast cancer. The grant is sponsored by the SNMMI Mars Shot Fund and the Lobular Breast Cancer Alliance.

• New PET Tracer Shows Promise for uPAR-Targeted Therapy of Neuroendocrine Neoplasms

  Sep 28, 2022 — A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms, according to research published in September JNM, and may also serve as a potential target for peptide radionuclide therapy (PRRT) for NEN patients.

• TerraPower Announces Funding Raised for Nuclear Technologies

  Sep 20, 2022 — TerraPower, a nuclear innovation company founded by Bill Gates, announced a $750 million funding raise co-led by Gates and SK, a large South Korean conglomerate that is one of South Korea’s largest energy providers. According to a press release from TerraPower, this effort will enhance the company’s “groundbreaking work in advanced nuclear energy technologies and nuclear medicine.”

• A Special Issue of the Journal of Nuclear Medicine Technology Highlights the New Frontier of Theranostics

  Sep 12, 2022 — A special issue of the Journal of Nuclear Medicine Technology focuses on theranostics as it relates to technologists and includes articles on quality and practice management, imaging, and radiation safety, as well as continuing education articles.

• SNMMI PR Campaign Lands Stories in Major Media Markets

  Sep 12, 2022 — SNMMI’s consumer-focused public relations initiative to raise awareness about what nuclear medicine is and what it can accomplish has seen continued success in the summer months.

• New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50 Percent of Prostate Cancer Patients

  Sep 7, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as compared to imaging with CT alone.

• The DOE Isotope Program Announces its Annual Medical Isotope User Group Meetings

  Aug 14, 2022 — In 2022, the Department of Energy (DOE) Isotope Program will host four virtual medical isotope user group meetings focused on the following emerging alpha and beta emitters: actinium-225, astatine-211, lead-212, and new this year, cerium-134.

• Crosby Elected Vice Chair of Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of SNMMI's Patient Advocacy Advisory Board.

• Francoeur to Lead Patient Advocacy Advisory Board for Society of Nuclear Medicine and Molecular Imaging

  Aug 11, 2022 — Jeri Francoeur of Ormond Beach, Florida, has been elected to a two-year term as chair of SNMMI's Patient Advocacy Advisory Board.

• The Journal of Nuclear Medicine Sheds Light on the Challenges of Medical Practice in Wartime Ukraine

  Aug 1, 2022 — The Journal of Nuclear Medicine has published a first-hand account of the daily practice of nuclear medicine and molecular imaging during the ongoing war in Ukraine.

• CMS releases its CY 2023 Medicare Physician Fee Schedule Proposed Rule

  Jul 14, 2022 — The Centers for Medicare and Medicaid Services (CMS) released its 2023 Medicare Physician Fee Schedule (MPFS) Proposed Rule on July 7.

• Safe and Equitable Healthcare for All: SNMMI’s Position on the Doctor-Patient Relationship

  Jul 8, 2022 — SNMMI statement: Safe and Equitable Healthcare for all: SNMMI’s position on the Doctor-Patient Relationship

• In the July Issue of The Journal of Nuclear Medicine

  Jul 6, 2022 — Editorial—Unacceptable denials of PSMA-Targeted PET/CT imaging … COVID-19 and the brain … Standard of care—Alzheimer disease … Radiotracers in cardiovascular imaging … Women authors in nuclear medicine journals … Featured: C-11-PiB PET in AL cardiac amyloidosis … Pretargeting and trastuzumab combination … and more.

• Journal of Nuclear Medicine Impact Factor Rises Again

  Jun 29, 2022 — The Journal of Nuclear Medicine has again achieved the highest impact factor in its history, ranking fourth among all medical imaging journals worldwide, according to new data just released in Clarivate's 2021 Journal Citation Reports.

• Aetna Reverses Cardiac PET/CT Non-Coverage & Updates Policy for PSMA Therapy

  Jun 27, 2022 — SNMMI and ASNC requested that Aetna reverse its non-coverage cardiac PET/CT policy. We are thrilled to communicate that within a few days of receiving our letter, Aetna reversed the policy. Also, Aetna recently updated and published their coverage policy for PSMA imaging for PLUVICTO therapy eligibility.

• CMS Reopens NCD for Beta Amyloid PET in Dementia and Neurodegenerative Disease

  Jun 24, 2022 — On June 16, 2022, the Centers for Medicare and Medicaid Services (CMS) began a reconsideration process for its National Coverage Determination (NCD) for Beta Amyloid Positron Emission Tomography (PET) in Dementia and Neurodegenerative Disease

• Nuclear Medicine and Molecular Imaging Community Gathers at SNMMI 2022 Annual Meeting

  Jun 16, 2022 — SNMMI hosted more than 6,700 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2022 Annual Meeting last week in Vancouver, British Columbia, Canada.

• SNMMI Image of the Year: New Biomarker Predicts Severity of Cardiac Remodeling after Heart Attack

  Jun 14, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, Ga-68-FAPI-46. The detailed depiction of Ga-68-FAPI-46 PET signal after acute anterior myocardial infarction has been selected as SNMMI’s 2022 Image of the Year.

• SNNMI Abstract of the Year: Targeted Radionuclide Treatment Achieves High Response Rate, Minimal Toxicities for Advanced-Stage Neuroendocrine Tumors

  Jun 14, 2022 — A targeted radionuclide alpha therapy, Ac-225 DOTATATE, has been shown to have long-term anti-tumor effects in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• PSMA PET Highlights Need for Updated Prostate Cancer Therapy Guidelines

  Jun 14, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET.

• Revolutionary Technology Shortens Cardiac Scan Time, Provides High-Quality SPECT Images

  Jun 14, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Novel Radiopharmaceutical Pair Detects and Treats Melanoma; Study Shows Potential for Broad Application in Solid Tumors

  Jun 14, 2022 — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• SNMMI Announces Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, as President of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Krystle W. Glasgow, MIS, CNMT, NMTCB(CT), NMAA, FSNMMI-TS, instructor and clinical coordinator at the University of Alabama at Birmingham in Birmingham, Alabama, has been elected as the 2022-23 president for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• SNMMI Elects Munir Ghesani, MD, FACNM, FACR, as President at 2022 Annual Meeting

  Jun 13, 2022 — Munir Ghesani, MD, FACNM, FACR, chief of nuclear medicine and molecular imaging at Mount Sinai Health System and associate professor of radiology at Mount Sinai Hospital in New York, NY, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

• SNMMI Launches Mars Shot Fund for Nuclear Medicine Research; Initial Donations Top $600,000

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced the creation of the Mars Shot Fund, an initiative to raise $100 million to help pay for research into nuclear medicine, molecular imaging, and therapy.

• SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as Vice President-Elect at 2022 Annual Meeting

  Jun 13, 2022 — Cathy Sue Cutler, PhD, FSNMMI, director of the medical isotope research and production program at Brookhaven National Laboratory in Upton, New York, has been named as vice president-elect for the Society of Nuclear Medicine and Molecular Imaging.

• SNMMI Announces Dmitry Beyder, CNMT, MPA, as President-Elect of the Technologist Section During 2022 Annual Meeting

  Jun 13, 2022 — Dmitry Beyder, CNMT, MPA, radiology program manager of nuclear medicine, PET, CT and patient transport at Barnes-Jewish Hospital/Mallinckrodt Institute of Radiology in St. Louis, Missouri, has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS).

• Simon R. Cherry, PhD, Receives 2022 Benedict Cassen Prize for Research in Molecular Imaging

  Jun 13, 2022 — Simon R. Cherry, PhD, known for his pioneering work in the development of PET technology and co-development of the EXPLORER total-body PET/CT scanner, was awarded the Benedict Cassen Prize during the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Andrei Iagaru, MD, FACNM, Receives Inaugural SNMMI Sam Gambhir Trailblazer Award

  Jun 13, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University, in Stanford, California, has been named as the first recipient of the Sam Gambhir Trailblazer Award.

• Society of Nuclear Medicine and Molecular Imaging Announces 2022 Fellows

  Jun 13, 2022 — The Society of Nuclear Medicine and Molecular Imaging recognized 15 new SNMMI Fellows on Monday, June 13, during a plenary session at the society’s 2022 Annual Meeting.

• Robert H. Mach, Phd, Receives SNMMI 2022 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science

  Jun 12, 2022 — Robert H. Mach, PhD, has been named the 2022 recipient of the prestigious Paul C. Aebersold Award.

• Molecular Imaging Biomarker Predicts Response to CAR T Cell Therapy

  Jun 12, 2022 — A new PET imaging agent, F-18 AlF-FAPI-74, has been found to effectively monitor and predict treatment response of CAR T cell therapy. This non-invasive imaging approach has the potential to help inform important clinical decision-making early in the course of treatment—including re-dosing of therapy, dose optimization, change of therapeutic course, and many more—to optimize patient outcomes.

• Virtual CT Scans Cut Patient Radiation Exposure in Half During PET/CT Studies

  Jun 12, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and subsequently decrease radiation exposure to the patient.

• Markus Schwaiger, MD, Receives SNMMI Georg Charles de Hevesy Nuclear Pioneer Award

  Jun 12, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

• PET Imaging Confirms Link Between Obstructive Sleep Apnea and Heart Blood Flow Impairment

  Jun 11, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart when needed, according to a first-of-its-kind PET imaging study presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

• Novel Ultra-Low Dose PET Technique Significantly Reduces Radiation Exposure

  Jun 11, 2022 — A new PET imaging technique can greatly reduce the amount of patient radiation exposure by eliminating the need for an accompanying CT scan. Without the CT scan, the amount of radiation delivered to the patient is cut dramatically, which benefits all patients, but in particular the pediatric population and those in need of multiple scans.

• New Targeted Radionuclide Alpha Therapy Improves Prostate Cancer Outcomes

  Jun 11, 2022 — A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer—225AC-NM600—has been shown to achieve significantly better outcomes than its corresponding targeted radionuclide beta therapy.

• Novel PET Agent Highly Effective for Imaging Meningiomas; Offers Logistical Advantages Over Standard Agents

  Jun 11, 2022 — A novel somatostatin-receptor (SSTR) targeting peptide—18F-SiTATE—has been shown to provide excellent imaging in patients with meningiomas, identifying bone involvement and lesions previously undetected on standard morphological imaging.

• PET/CT Effective in Evaluating and Monitoring Post-COVID-19 Lung Disease

  Jun 11, 2022 — F-18 FDG PET/CT has been proven successful in evaluating lung inflammation and monitoring treatment effects in patients suffering from post-COVID-19 lung disease.

• JNM Supplement Explores Opportunities for Molecular Imaging of Neurodegeneration

  Jun 2, 2022 — In response to the ongoing paradigm shift in how neurodegenerative diseases are defined and diagnosed—as well as the new hope for a breakthrough in disease-modifying drugs—The Journal of Nuclear Medicine has issued a supplement on molecular imaging of neurodegeneration.

• In the June Issue of The Journal of Nuclear Medicine

  Jun 1, 2022 — In the June issue of JNM: A Letter from Ukraine … Discussion with Peter J. O’Dwyer: Precision medicine in cooperative trials … Issues and Controversies: The VISION Forward … The State of the Art: Guidelines for theranostics … Continuing Education: Lu-177-PSMA and prostate cancer … Hot Topics: Tau, amyloid, and atrophy … Featured: PET and DLBCL response … Radiotherapy ligands for FAP … and more.

• SNMMI & Partners Urge Congress to Support Increased Federal Research Funding

  May 16, 2022 — SNMMI and 368 members of the Ad Hoc Group for Medical Research sent a letter to Congress requesting that the Labor-HHS Subcommittee be allocated sufficient funding to allow for investment in NIH and other agencies that promote the health of our nation. The letter also urged Congress to work expeditiously to complete FY 2023 appropriations in a timely manner.

• Iohexol (Omnipaque) and Iodixanol (Visipaque) Shortage

  May 12, 2022 — A shortage of iohexol (Omnipaque) is occurring as a result of the Chinese government lockdowns related to COVID-19. The alternative agent, iodixanol (Visipaque), is in short supply due to an increase in demand.

• Novartis Announces Temporary Halt in Production of Lutathera and Pluvicto

  May 5, 2022 — On May 5, Novartis announced that it will temporarily suspend production of Lutathera and Pluvicto at its radioligand therapy production sites in Ivrea, Italy, and Milburn, New Jersey, affecting both commercial and clinical trial supply.

• Active Brown Adipose Tissue Protects Against “Pre-Prediabetes”

  May 4, 2022 — In a prospective study of young, lean adults, PET/CT imaging revealed that higher levels of active brown adipose tissue (also known as “brown fat”) are more prevalent in individuals who exhibit very early indications of metabolic disorders. The research was published ahead of print in The Journal of Nuclear Medicine.

• JNM Publishes Joint Guide for the Establishment of Theranostics Centers

  Apr 29, 2022 — SNMMI, the European Association of Nuclear Medicine, and the International Atomic Energy Agency have created a new guide for the creation of dedicated theranostics centers.

• SNMMI and Partners Request a Hearing for the FIND Act

  Apr 28, 2022 — This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.

• Novel Deep Learning Method Provides Early and Accurate Differential Diagnosis for Parkinsonian Diseases

  Apr 21, 2022 — A new deep learning method has been created to aid in the diagnosis of parkinsonian diseases, according to research published in JNM.

• SNMMI Hosts AI and Patient Access Summits

  Mar 28, 2022 — On March 21-23, SNMMI hosted two summits in Bethesda, MD, on Artificial Intelligence and Barriers to Patient Access. The aim of the summits—the first of their kind for the society—was to bring together thought leaders to discuss current obstacles in the field of nuclear medicine and provide solutions. Read the highlights.

• New Issue of Clinical Trials Newsletter "Pathways" Now Available

  Mar 11, 2022 — The February 2022 issue of the SNMMI Clinical Trials Network newsletter, Pathways, is now available online.

• SNMMI Supports ARPA-H Act

  Mar 4, 2022 — SNMMI signed on as a supporting organization to the Advanced Research Project Agency Health (ARPA-H) Act and offered to be a resource as the bill's sponsor continues to refine the legislative text.

• SNMMI Statement on Aggression in Ukraine

  Mar 1, 2022 — SNMMI deplores the recent invasion of Ukraine that has resulted in the death and injury of a large number of innocent men, women, and children—a horrifying contrast to our work to save lives and improve patient care.

• SNMMI COVID-19 Task Force Vaccination Recommendation

  Feb 28, 2022 — The SNMMI COVID-19 Task Force strongly urges all eligible SNMMI members and healthcare professionals to be vaccinated and receive a booster as soon as possible.

• SNMMI Advocates for Expanded Coverage & Reimbursement of Amyloid PET

  Feb 17, 2022 — When CMS issued a national coverage determination analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, SNMMI took action.

• Now Available! PET/CT in Oncology 2021: Part 1

  Oct 7, 2021 — The SNMMI-TS has just released a new book in the SNMMI-TS Quality and Safety Series: PET/CT in Oncology 2021: Part 1. Members can now access the PDF version and interactive online edition free of charge, or receive a 50% discount on the printed book available in the SNMMI Store.

• Introducing the SNMMI Annual Awards Guide

  Sep 30, 2021 — The SNMMI is excited to publish its first comprehensive awards publication, SNMMI Annual Grants & Awards Recognition, highlighting the recipients of the many honors, awards, grants, and scholarships presented by the SNMMI and SNMMI-TS in the past year.

• SNMMI Announces Ones to Watch 2021 Selections

  Jul 16, 2021 — SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2021!

• SNMMI Authors Member Template Letter for SPECT/CT Coverage Denials

  Jun 3, 2021 — After many complaints from our members about SPECT/CT coverage denials from various commercial payers, SNMMI has put forth a resource members can use to contest these decisions.

• Celebrating Pride Month

  Jun 1, 2021 — SNMMI is proud to recognize and support our LGBTQ+ members with Pride Month celebrations throughout June! At SNMMI, we are committed to celebrating diversity and championing an inclusive, safe, and welcoming environment that respects each member of our professional and patient community. We encourages all nuclear medicine and molecular imaging professionals to actively participate in these efforts.

• Now Available and Free to Members! PET/CT in Oncology: Part 2

  Mar 31, 2021 — The SNMMI-TS has just released a new book in the SNMMI-TS Quality and Safety Series: PET/CT in Oncology 2021: Part 2. Members can access the digital versions free of charge or receive a 50% discount on the printed book, now available in the SNMMI Store.

• NRC Unveils Patient Educational Video on Radioactive Drug Therapy

  Jan 26, 2021 — Last week, the U.S. Nuclear Regulatory Commission (NRC) announced the release of the video, “Staying Safe While Getting Better, Protecting Yourself and Your Loved Ones While Taking Radioactive Drugs.”

• Celebrating Women in Medicine Month

  Sep 5, 2019 — September 5 is Women in Medicine Day and SNMMI is excited to join the American Medical Association (AMA) in celebrating Women in Medicine Month throughout September! We will be honoring this year’s theme, “Women in Medicine: Trailblazers, Advocates, Leaders,” all month long, recognizing the achievements, contributions, and trailblazing efforts of women in our nuclear medicine and molecular imaging community.

• Fall Education Preview

  Aug 28, 2019 — We know you're busy. That's why you need on-demand access to industry news, research, and education available at your fingertips. SNMMI offers a wide variety of programs that provide relevant and timely educational content for nuclear medicine and molecular imaging professionals at every stage in their career. See the SNMMI Education Fall Preview below and register now for the professional development events best suited to your needs.

• New Radiotracer Can Identify Nearly 30 Types of Cancer: Future potential for therapeutic application

  Jun 7, 2019 — A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors, according to research published in the June issue of The Journal of Nuclear Medicine.

• Ones to Watch – Early Career Professionals Making a Difference in 2019

  Mar 18, 2019 — We are proud to present this selection of 30 rising stars in nuclear medicine and molecular imaging. With help from the Committee on Councils and Centers and the SNMMI-TS Professional Development Task Force, SNMMI has identified these young professionals as “Ones to Watch” in 2019. The future looks bright!

• This Month in JNM

  Dec 3, 2018 — The December 2018 issue of The Journal of Nuclear Medicine is now available. Read about three novel tau radiopharmaceuticals for imaging patients with amyloid-positive Alzheimer disease, whole-body 68Ga-PSMA-11 PET/MR, immuno-PET after BACE-1 inhibition, and more. Also, check out the first in a new series of articles: "Discussions with Leaders."

• This Month in JNM

  Nov 1, 2018 — The November 2018 issue of The Journal of Nuclear Medicine is now available. Read about c-Met-targeted imaging of non-small cell lung cancer, Ga-68-PSMA-11 PET/CT for radiation treatment planning, the current state of radiopharmaceutical therapy, and more.

• This Month in JNM

  Oct 1, 2018 — The October 2018 issue of The Journal of Nuclear Medicine is now available. Read about PET imaging for nicotinic acetylcholine receptors, imaging liver lymphocytes and more!

• USP Plans to Establish New Chapter for Radiopharmaceuticals and Calls for Candidates on Expert Panel

  Jun 2, 2017 — The USP plans to establish a new General Chapter <825> Compounding-Radiopharmaceuticals.

• 2017 Robert E. Henkin Government Relations Fellowship

  May 31, 2017 — The fellows spent a week in Washington, DC, and gained firsthand knowledge of Capitol Hill and inside federal agencies.

• FDA Issues Draft Guidances on Compounding and Repackaging Radiopharmaceuticals

  Jan 11, 2017 — The FDA issued two draft guidances that describe FDA’s proposed policies regarding the compounding and repackaging of radiopharmaceuticals for human use by state-licensed nuclear pharmacies or federal facilities, and outsourcing facilities.

• SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals

  Dec 14, 2016 — SNMMI has developed USP Recommendations for Compounded Sterile Radiopharmaceuticals.